Recent therapeutic trends and promising targets in triple negative breast cancer.
作者： Soo-Yeon Hwang , Seojeong Park , Youngjoo Kwon
DOI: 10.1016/J.PHARMTHERA.2019.02.006
关键词:
摘要: Breast cancer accounts for 25% of all types of cancer in women, and triple negative breast cancer (TNBC) comprises around 15~ 20% of breast cancers. Conventional chemotherapy …
sci-hub.se 参考文章(324)
L Adams-Campbell, L Rosenberg, J R Palmer, The Black Women's Health Study: a follow-up study for causes and preventions of illness Journal of the American Medical Women's Association. ,vol. 50, pp. 56- 58 ,(1995)
Shaham Beg, Abdul K. Siraj, Sarita Prabhakaran, Zeenath Jehan, Dahish Ajarim, Fouad Al-Dayel, Asma Tulbah, Khawla S. Al-Kuraya, Loss of PTEN expression is associated with aggressive behavior and poor prognosis in Middle Eastern triple-negative breast cancer Breast Cancer Research and Treatment. ,vol. 151, pp. 541- 553 ,(2015) , 10.1007/S10549-015-3430-3
Denise A. Yardley, Dianna L. Shipley, Nancy W. Peacock, Mythili Shastry, Rajiv Midha, Victor M. Priego, John D. Hainsworth, Phase I/II trial of neoadjuvant sunitinib administered with weekly paclitaxel/carboplatin in patients with locally advanced triple-negative breast cancer. Breast Cancer Research and Treatment. ,vol. 152, pp. 557- 567 ,(2015) , 10.1007/S10549-015-3482-4
Robin Dufour, Pierre Daumar, Emmanuelle Mounetou, Corinne Aubel, Fabrice Kwiatkowski, Catherine Abrial, Catherine Vatoux, Frédérique Penault-Llorca, Mahchid Bamdad, BCRP and P-gp relay overexpression in triple negative basal-like breast cancer cell line: a prospective role in resistance to Olaparib. Scientific Reports. ,vol. 5, pp. 12670- 12670 ,(2015) , 10.1038/SREP12670
Hong Zhang, David M. Conrad, Jared J. Butler, Chuanli Zhao, Jonathan Blay, David W. Hoskin, Adenosine Acts through A2 Receptors to Inhibit IL-2-Induced Tyrosine Phosphorylation of STAT5 in T Lymphocytes: Role of Cyclic Adenosine 3′,5′-Monophosphate and Phosphatases Journal of Immunology. ,vol. 173, pp. 932- 944 ,(2004) , 10.4049/JIMMUNOL.173.2.932
Tiffany A Traina, Joyce O'Shaughnessy, Rita Nanda, Lee Schwartzberg, Vandana Abramson, Javier Cortes, Amy Peterson, Iulia Cristina Tudor, Martha Blaney, Joyce L Steinberg, Catherine Kelly, Maureen Trudeau, Ahmad Awada, Eric Winer, Clifford Hudis, Peter Schmid, Denise A Yardley, Abstract P5-19-09: Preliminary results from a phase 2 single-arm study of enzalutamide, an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC) Cancer Research. ,vol. 75, ,(2015) , 10.1158/1538-7445.SABCS14-P5-19-09
Si-Meng Chen, Chen-Liang Guo, Jia-Jie Shi, Yi-Chao Xu, Yi Chen, Yan-Yan Shen, Yi Su, Jian Ding, Ling-Hua Meng, HSP90 inhibitor AUY922 abrogates up‐regulation of RTKs by mTOR inhibitor AZD8055 and potentiates its antiproliferative activity in human breast cancer International Journal of Cancer. ,vol. 135, pp. 2462- 2474 ,(2014) , 10.1002/IJC.28880
Hiroyuki Motoshima, Barry J. Goldstein, Motoyuki Igata, Eiichi Araki, AMPK and cell proliferation – AMPK as a therapeutic target for atherosclerosis and cancer The Journal of Physiology. ,vol. 574, pp. 63- 71 ,(2006) , 10.1113/JPHYSIOL.2006.108324
Aamer Farooq, Muhammad M. Mirza, Jasgit C. Sachdev, Saira Ahmed, Mohammad Jahanzeb, Lori Kronish, Does Race Affect Outcomes in Triple Negative Breast Cancer Breast Cancer: Basic and Clinical Research. ,vol. 4, pp. 23- 33 ,(2010) , 10.4137/BCBCR.S0
Brian D. Lehmann, Jennifer A. Pietenpol, Antoinette R. Tan, Triple-Negative Breast Cancer: Molecular Subtypes and New Targets for Therapy American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. ,vol. 35, pp. 31- 39 ,(2015) , 10.14694/EDBOOK_AM.2015.35.E31